<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2022</year>
    <pub-dates>
     <date>2023-04-12</date>
    </pub-dates>
   </dates>
   <doi>10.18137/cardiometry.2022.24.198203</doi>
   <abstract>The paper discusses the features of antithrombotic therapy of&#13;
pregnant women suffering from congenital cardiopathologies.&#13;
Providing medical care to women suffering from cardiovascular&#13;
diseases and carrying a child is a difficult task due to the unique&#13;
maternal physiology, which causes profound changes in many&#13;
organ systems. First of all, such difficulties are caused by the&#13;
presence of the fetus, since individual approaches to the treatment of cardiac diseases of the mother can have an adverse&#13;
disease on the child. Conversely, the patient’s refusal of the necessary treatment due to potential harm to the fetus is fraught&#13;
with a bad outcome for both the mother and the child. Physiological adaptation of the mother’s body during pregnancy can&#13;
provoke cardiometabolic complications and cause thrombosis,&#13;
the consequences of which can be fatal. Accordingly, the development of approaches to the organization of antithrombotic&#13;
therapy of pregnant patients with cardiopathologies can contribute to improving the survival of the mother and fetus during&#13;
pregnancy, as well as create prerequisites for a successful delivery and postpartum recovery of the woman and child.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/4192</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/4368</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
